CURE

FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...
Targeted Oncology

FDA Approves Extended-Release Ruxolitinib Once-Daily for MPNs and GVHD

FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...

Incyte Announces FDA Approval of Jakafi XRâ„¢ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XRâ„¢ (ruxolitinib) ...